Policy Proposal · May 2026

Medical Cannabis Reform for Ireland

A comprehensive five-pillar reform package for the Medical Cannabis Access Programme (MCAP) — prepared for Oireachtas members, the Department of Health, HSE, and HPRA.

Read the Proposal Download & Share

🌿

Five Reform Pillars

Comprehensive MCAP overhaul

1 Clinic Licensing & Expansion
2 Equitable Patient Access
3 Reducing Red Tape & Investment
4 International Patient Framework
5 Expanded Medical Indications

Current qualifying conditions under MCAP

New indications proposed

Reform pillars

Workstreams in the roadmap

Background

Ireland's Current Framework

Cannabis containing THC is Schedule 1 under the Misuse of Drugs Acts 1977–2016 and Misuse of Drugs Regulations 2017 — the highest level of control. The MCAP was first enabled in 2019 following the HPRA's "Cannabis for Medical Use" scientific review, to provide compassionate access where conventional treatment has failed.

The programme operates through the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019, most recently amended by S.I. No. 229 of 2025. Despite these improvements, Ireland lags behind Germany, the Netherlands, and Denmark in terms of access, investment, and commercial attractiveness.

Access Pathways

There are two routes to accessing medical cannabis in Ireland. Both are heavily bureaucratic, and neither adequately serves the range of patients who could benefit from cannabinoid therapy.

HSE Reimbursement Scheme

Funding Available — But Constrained

Eligible MCAP patients can apply for funding of approved cannabis-based products. However, the process requires consultant involvement, significant documentation, and is limited to a narrow list of approved products available through a small number of specialist clinics.

MCAP Route

For patients with one of three specified conditions under the care of a specialist consultant, registered on the Cannabis for Medical Use Register.

Ministerial Licence Route

For individual named patients — typically for chronic pain, certain psychiatric/neurological conditions, oncology, and palliative care — subject to detailed clinical application and ministerial approval.

Reform Proposals

Five Pillars of Reform

These reforms align with international best practice, respect Ireland's obligations under EU and international law, and present an opportunity to enhance patient care while positioning Ireland as a responsible, innovation-friendly medical cannabis hub.

Clinic Licensing & Expansion

Create a statutory medical cannabis clinic licence category under HPRA and Department of Health oversight. Currently there is no national licensing framework, leading to long waiting times and regional disparities.

Statutory clinic licence under HPRA oversight
Open to public and private clinics in primary care networks
Mandatory cannabinoid medicine training (Medical Council accreditation)
Telemedicine for follow-up and stable patients
Mandatory data contribution to national cannabis registry

Equitable Patient Access

Expand the MCAP indication list and introduce tiered prescribing authority to allow trained GPs to initiate and continue prescribing for specified indications, reducing bottlenecks at hospital level.

Expand indications to include chronic pain, PTSD, IBD, oncology
Tiered prescribing: GPs for stable cases, specialists for complex
Standardise reimbursement via Medical Card & Drug Payment Scheme
Simplify renewal — annual reviews for stable patients
Develop national clinical guidelines and dosing protocols

Reducing Red Tape & Investment

Streamline complex regulatory landscape to attract responsible domestic and international investment, broaden product availability, and leverage Ireland's pharmaceutical expertise.

Mutual recognition for EU-authorised cannabis products
Single-window application system (HPRA + customs + licensing)
Domestic cultivation and processing licence regime
R&D tax credits and IDA-supported grants
Medical Cannabis Industry Advisory Group

International Patient Framework

Introduce a clear, compassionate protocol for international patients travelling to Ireland with legally prescribed medical cannabis — currently they face seizure risk and potential criminal liability at ports of entry.

Visiting Patient Protocol — up to 30-day personal supply
Pre-travel notification system via HPRA / Controlled Drugs Unit
Operational guidance to Revenue, Garda Síochána, airports & ports
Exceptional authorisations for extended stays

Expanded Medical Indications

Adopt an adaptive, evidence-based tiered indication framework that allows Ireland to respond to evolving scientific knowledge while maintaining appropriate caution. Mandate a periodic HPRA scientific review every three years.

Tiered framework: strong evidence / emerging evidence / compassionate
3-year periodic HPRA review with clinical and patient input
Integrate ministerial-licence indications with MCAP over time
Patient-reported outcomes data collection mandate

Pillar 2 & 5 Detail

Expanding Qualifying Conditions

The current three-condition MCAP list reflects an early, cautious approach. International experience and research have since expanded the evidence base considerably.

Currently Qualifying (3 conditions)

✅ MS-related spasticity
✅ Severe refractory epilepsy
✅ Chemotherapy-induced nausea & vomiting

Proposed Additions

➕ Chronic neuropathic & other chronic pain
➕ PTSD & treatment-resistant anxiety/depression
➕ Parkinson's & neurodegenerative conditions
➕ Inflammatory bowel disease (Crohn's & UC)
➕ Oncology symptoms & palliative care
➕ MS beyond spasticity & chronic fatigue

Proposed Tiered Framework

Tier 1

Strong Evidence & Established Protocols

Full MCAP listing. Eligible for standard reimbursement via Medical Card and Drug Payment Scheme. GP prescribing permitted.

Tier 2

Emerging Evidence — Supervised Use

Warranting supervised, monitored use within registries or controlled access schemes. Specialist oversight required. Patient-reported outcomes collected.

Tier 3

Insufficient Evidence — Compassionate Use

Exceptional access under strict criteria, mirroring the current ministerial licence approach. Case-by-case assessment with full clinical justification.

Periodic Review: HPRA mandated to conduct a scientific review of the evidence base every three years, with external clinical and patient input, to update the tiered framework as evidence evolves.

Implementation

Delivery Roadmap

Timelines assume political commitment and adequate resourcing. Many reforms can be progressed in parallel through a cross-departmental implementation group.

Reform Area	Lead Body	Key Supporting Bodies	Suggested Timeline
Expansion of MCAP indications	HPRA / Dept. of Health	HSE, Clinical Colleges	6–12 months
International patient protocol	Department of Health	HPRA, Revenue, Garda Síochána	6–12 months
Clinic licensing framework	Dept. of Health / HPRA	Medical Council, HSE	12–18 months
GP prescribing & national guidelines	Dept. of Health / Medical Council	ICGP, HSE	12–18 months
Streamlined licensing & mutual recognition	HPRA	Revenue, Dept. of Enterprise	12–18 months
National registry & data systems	HSE	HPRA, Licensed Clinics	12–18 months
Domestic cultivation & processing framework	HPRA / Dept. of Agriculture	Dept. of Enterprise, IDA	18–24 months

Resources

Policy Presentation & Document

The full 15-slide presentation and the original policy document are available to download, share, and adapt for briefings, meetings, and advocacy purposes.

Medical Cannabis Policy Reform

A professionally designed presentation covering all five reform pillars, the implementation roadmap, the expanded indications framework, and the international patient protocol — built for advocacy meetings and public briefings.